Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib plus ruxolitinib vs placebo plus ruxolitinib in myelofibrosis
CTR20213340Phase 3Terminated
- Sponsor
- Incyte
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of parsaclisib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), myelofibrosis (MF), sponsored by Incyte. Started Jan 2022; status: terminated.
02
Drugs
parsaclisib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20213340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213340.